A California-based company is seeking US Food and Drug Administration (FDA) authorisation to market what it calls the first “vapour-style inhalable” nicotine replacement therapy (NRT) device ...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.
